In the post-war period the following BCG vaccines were successively in use for preventive vaccination in the Czech territory : (a) Copenhagen BCG, 1947-1950, (b) Prague BCG 725,1951-1980, (c) Moscow BCG, 1981-1993, and (d) Behring BCG, from 1994 onwards.
These BCG substrains can be now identified by modern methods of molecular genetics.
Introducing the Moscow BCG brought about an elevated incidence of iatrogenic local and regional lymph node adverse reactions compared with the previous Prague BCG product and, as a new phenomenon, bone and joint involvements in children vaccinated at birth.
The aim of this study was to analyze the incidence of postvaccination adverse reactions reported in the period from 1981 to 1993 as related to the Moscow BCG vaccine and, to demonstrate the effect of lower vaccination dosage on their frequency.
The concentration of the Moscow BCG varied from 11 to 22.6 x 106 (average 16.2) CFU per 1 mg.
Mots-clés Pascal : BCG, Vaccination, Prévention, Complication, Homme, Epidémiologie, Mycobacterium bovis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bactérie, République tchèque, Europe
Mots-clés Pascal anglais : BCG, Vaccination, Prevention, Complication, Human, Epidemiology, Mycobacterium bovis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bacteria, Czech Republic, Europe
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0595472
Code Inist : 002B05B02P. Création : 01/03/1996.